ClinicalTrials.gg
Active, not recruitingNCT07391241Updated Nov 6, 2026

A Phase 2 Study to Evaluate the Efficacy and Safety of Pudafensine in Vulvodynia (Provoked Vestibulodynia)

A Phase 2 interventional study of Pudafensine in Vulvodynia, sponsored by Initiator Pharma. Active, not recruiting at 1 site in United Kingdom. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Initiator Pharma · Phase 2, Interventional, and Treatment

Updated Nov 6, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Study summary

The study (IP2015CS05) is a randomised, double-blind, placebo-controlled, 4-way cross-over trial studying the efficacy and safety of single dose administration of pudafensine in vulvodynia (provoked vestibulodynia) patients.

02

Conditions studied

  • Vulvodynia

Browse trials for

03

In context

Vulvodynia

117 studies on the registry are indexed under Vulvodynia; 21 are open to participants now.

This study's planned enrollment of 24 is below the median of 46 across 89 interventional studies indexed under Vulvodynia.

Browse Vulvodynia studies →

Lead sponsor

Initiator Pharma is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant with vulvodynia (provoked vestibulodynia).

Exclusion criteria

Exclusion Criteria:

  • Women with vulvar pain caused by a specific disorder:

    1. Infectious (e.g. recurrent candidiasis, herpes).
    2. Inflammatory (e.g. lichen sclerosus, lichen planus, immunobullous disorders).
    3. Neoplastic (e.g. Paget disease, squamous cell carcinoma).
    4. Neurologic (e.g. postherpetic neuralgia, nerve compression or injury, neuroma).
    5. Trauma (e.g. female genital cutting, obstetrical).
    6. Iatrogenic (e.g. postoperative, chemotherapy, radiation).
    7. Hormonal deficiencies (e.g. genitourinary syndrome of menopause (vulvovaginal atrophy), lactational amenorrhea).
  • History or current diagnosis of significant pelvic floor dysfunction.
  • Co-morbid pelvic pain conditions including pain due to pelvic fractures, pelvic girdle pain or post-partum pelvic pain (to avoid confounding pain outcomes).
  • History or current diagnosis of pelvic inflammatory disease.
  • History or current diagnosis of endometriosis.
  • History or current diagnosis of interstitial cystitis.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Dose_1

    Pudafensine

    Drug: Pudafensine

  • Experimental
    Dose_2

    Pudafensine

    Drug: Pudafensine

  • Experimental
    Dose_3

    Pudafensine

    Drug: Pudafensine

  • Placebo comparator
    Placebo

    Placebo

    Drug: Pudafensine

Interventions

06

What researchers measure

Primary outcomes

  1. The primary objective of this study is to evaluate the effect of pudafensine on pain in the vaginal vestibule (vestibular pain threshold) using the Vestibular Pain Threshold Test

    Time frame: Through study completion, an average of 1 year

07

Study locations

1 site
  • MAC
    Blackpool, United Kingdom
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Sep 2026 → Dec 2026 and completion Dec 2026 → Feb 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2026
First posted
Feb 5, 2026
StartActual
Dec 17, 2025
Primary completionEst.
Dec 31, 2026was Sep 2026
CompletionEst.
Feb 25, 2027was Dec 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 6, 2026
Primary completion
Sep 1, 2026→Dec 31, 2026
Nov 6, 2026
Study completion
Dec 1, 2026→Feb 25, 2027
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Recruiting→Active, not recruiting
    Primary completion Sep 1, 2026→Dec 31, 2026
    Study completion Dec 1, 2026→Feb 25, 2027
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07391241
Lead sponsor
Initiator Pharma
Responsible party
Sponsor
First posted
Feb 5, 2026
Start date
Dec 17, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Feb 25, 2027 (estimated)
Last update
Nov 6, 2026

Study contacts

Abimbola Babajide, Dr
principal investigator · MAC, UK

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pudafensine

Start the discussion